Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant777 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,522 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05044091 | Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients(HOPEI) | unknown | — | 100 | Xiaoxiang ChenOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT04217798 | Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Peking Union Medical College HospitalOTHER | 1 | Sep 1, 2021 |
| clinicaltrials |
| NCT03462212 | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination(MITO25) | unknown | Phase 1 / Phase 2 | 290 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04679064 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment(NItCHE-MITO33) | unknown | Phase 3 | 427 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04617470 | Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study(MITO 34) | unknown | — | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03814447 | The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer | unknown | Early Phase 1 | 10 | Shanghai 6th People's HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04267575 | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | unknown | N/A | 20 | Jerome Canady, M.D.OTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04887961 | Reprab Study: PLD + Trabectedin Rechallenge(MITO36) | unknown | Phase 2 | 64 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04986371 | Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer(RENI-1) | unknown | — | 300 | Ling-Ying WuUNKNOWN | 0 | Aug 2, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT04971421 | Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian Cancer(OVI-DETECT) | unknown | — | 450 | The Netherlands Cancer InstituteOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04734665 | Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor(NIRVANA-R) | unknown | Phase 2 | 44 | Yonsei UniversityOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT02758652 | Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer(CHEMOVA) | unknown | — | 160 | Tampere University HospitalOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT01611766 | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? | unknown | Phase 3 | 356 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 10, 2021 | clinicaltrials |
| NCT03709316 | A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | unknown | Phase 3 | 384 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04911114 | Targeted Physical Activity to Improve Mobility and Falls Risk in Women Living With Ovarian Cancer(BE-BALANCED) | unknown | N/A | 30 | University of British ColumbiaOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04556539 | Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer | unknown | Phase 2 | 104 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 12, 2021 | clinicaltrials |
| NCT00703105 | Ovarian Dendritic Cell Vaccine Trial | unknown | Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04361370 | Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer(OPEB-01) | unknown | Phase 2 | 44 | Yonsei UniversityOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04337632 | Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer | unknown | Phase 3 | 338 | Hunan Cancer HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04828616 | Study of DP303c Injection in Patients With Advanced Ovarian Cancer | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 2, 2021 | clinicaltrials |
| NCT04815408 | PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer | unknown | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT04812938 | Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test(PAPAudit) | unknown | — | 190 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03000192 | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | unknown | — | 3,000 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04747717 | Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer | unknown | N/A | 30 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04714931 | Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5) | unknown | N/A | 200 | Acibadem UniversityOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02247323 | Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125(CA125) | unknown | — | 200 | Beni-Suef UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer(CLIO) | unknown | Phase 2 | 160 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04582552 | The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer(ROMP) | unknown | — | 60 | Xiaoxiang ChenOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04695015 | Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm | unknown | — | 100 | Peking UniversityOTHER | 0 | Jan 5, 2021 | clinicaltrials |
| NCT04661696 | Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. | unknown | Phase 2 | 75 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04651933 | A Training Set for the HRD Model in EOC | unknown | — | 200 | Lei LiOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04651946 | Cell-free DNA Methylation for Epithelial Ovarian Cancer | unknown | Phase 2 | 400 | Lei LiOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04376073 | Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer(ANNIE) | unknown | Phase 2 | 40 | Jihong LiuOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04556071 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer(AVANIRA3) | unknown | Phase 2 | 32 | Xiaoxiang ChenOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04566952 | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer(ANLOLA) | unknown | Phase 2 | 68 | Xiaoxiang ChenOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04590625 | Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer | unknown | Phase 2 | 58 | Zhongshan Hospital Xiamen UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03899610 | A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)(KGOG3046) | unknown | Phase 2 | 24 | Yonsei UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04555473 | Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids(TAILOR) | unknown | — | 48 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT04279509 | Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) | unknown | N/A | 35 | National University Hospital, SingaporeOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04473339 | A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation | unknown | Phase 3 | 280 | CAI HongbingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04402333 | Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival(MIRRORS) | unknown | — | 40 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT04528940 | Tumor Grade Determines PD-1/PDL-1 Expression | unknown | — | 100 | RWJ Barnabas Health at Jersey City Medical CenterOTHER | 1 | Aug 27, 2020 | clinicaltrials |
| NCT00652119 | Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin | unknown | Phase 1 | 46 | Massachusetts General HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04504110 | 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04503980 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | unknown | Early Phase 1 | 10 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Aug 7, 2020 | clinicaltrials |
| NCT04489706 | Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation | unknown | N/A | 20 | Ruijin HospitalOTHER | 1 | Jul 28, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Sep 14, 2021source: clinicaltrials